Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2003099833) BETA-2-GLYCOPROTEIN 1 IS AN INHIBITOR OF ANGIOGENESIS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2003/099833 International Application No.: PCT/US2003/010188
Publication Date: 04.12.2003 International Filing Date: 02.04.2003
IPC:
A61K 38/17 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
Applicants:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street Suite 820 Austin, TX 78701, US (AllExceptUS)
SCHROIT, Alan, Jay [US/US]; US (UsOnly)
BALASUBRAMANIAN, Krishnakumar [IN/US]; US (UsOnly)
MCCARTY, Marya, F. [US/US]; US (UsOnly)
Inventors:
SCHROIT, Alan, Jay; US
BALASUBRAMANIAN, Krishnakumar; US
MCCARTY, Marya, F.; US
Agent:
SAMPSON, Margaret, J.; Vinson & Elkins L.L.P. 2300 First City Tower 1001 Fannin Street Houston, TX 77002-6760, US
Priority Data:
60/381,21917.05.2002US
Title (EN) BETA-2-GLYCOPROTEIN 1 IS AN INHIBITOR OF ANGIOGENESIS
(FR) LA BETA-2-GLYCOPROTEINE 1 EST UN INHIBITEUR DE L'ANGIOGENESE
Abstract:
(EN) The present disclosure provides a method of inhibiting angiogenesis within a tissue of interest by providing either intact or nicked &bgr;2-Glycoprotein 1(&bgr;2GP1) to cells associated with the tissue. The presence of &bgr;2GP1 inhibits angiogenesis within the tissue, in part by preventing neovascularization into the tissue. The disclosure also provides a method for treating tumors by providing &bgr;2GP1 to the tumor.
(FR) L'invention concerne un procédé permettant d'inhiber l'angiogenèse dans un tissu spécifique, par l'apport de $g(b)2-glycoprotéine 1 ($g(b)2GP1), soit intacte, soit coupée, aux cellules associées à ce tissu. La présence de $g(b)2GP1 inhibe l'angiogenèse dans le tissu, notamment en empêchant la néovascularisation dans ce dernier. L'invention concerne également une méthode de traitement antitumoral consistant à apporter du $g(b)2GP1 à la tumeur.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP1515754AU2003273176